Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: Biomarin pharmaceutical | Rare Historical Photos

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings

Biomarin Pharmaceutical Inc (NASDAQ:BMRN) reported weaker-than-expected earnings for the third quarter on Monday.

2 'Strong Buy'-Rated Stocks That Could Rally 39% to 48% in 2025

2 'Strong Buy'-Rated Stocks That Could Rally 39% to 48% in 2025

Both of these growth stocks are positioned for long-term success.

3 Biotech Stocks Beating BioMarin Pharmaceutical (BMRN)

3 Biotech Stocks Beating BioMarin Pharmaceutical (BMRN)

Breakthrough developments, the use of advanced technologies, and rising investments in R&D are some of the factors driving the growth of the biotech industry. Although BioMarin Pharmaceutical (BMRN) showcases strong growth prospects, investors could consider buying even better biotech stocks Amgen (AMGN), Jazz Pharmaceuticals (JAZZ), and Vertex Pharmaceuticals (VRTX). Read…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Widening tech, biotech job cuts could jolt broader Bay Area economy: experts

SAN JOSE, Calif. — Bay Area tech and biotech companies have recently revealed plans to chop thousands of jobs, layoffs that raise the specter that these cutbacks might haunt the region’s broader economy.

Tribune News Service

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Hundreds of tech and biotech layoffs rattle Bay Area job market

REDWOOD CITY, California — A tech titan and a biotech company revealed plans to chop nearly 300 jobs in the Bay Area, hinting at unsettling prospects for the region’s employment sector.

Tribune News Service

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

inkl

Read news from The Economist, FT, and more,
with one subscription

What 4 Analyst Ratings Have To Say About Biomarin Pharmaceutical

What 4 Analyst Ratings Have To Say About Biomarin Pharmaceutical

Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter:

Biomarin Pharmaceutical Earnings Preview

Biomarin Pharmaceutical Earnings Preview

Biomarin Pharmaceutical (NASDAQ:BMRN) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Biomarin Pharmaceutical will report an earnings per share (EPS) of $0.17.

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

A Bearish Sign Appears On Biomarin Pharmaceutical's Chart

A Bearish Sign Appears On Biomarin Pharmaceutical's Chart

If history is any guide, there may be trouble ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Recap: Biomarin Pharmaceutical Q4 Earnings

Recap: Biomarin Pharmaceutical Q4 Earnings

Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Biomarin Pharmaceutical reported in-line EPS of $-0.32 versus an estimate of $-0.32.

1

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Macular Degeneration

Places

364,322 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play